
Sincere invitation

From November 17 to 19, 2026, the globally renowned industry event in the biopharmaceutical community—PEGS 2026 Europe—will grandly open in Lisbon, Portugal. As a top international forum in the fields of protein engineering and molecular biology, this conference will bring together scientists and industry leaders from top global pharmaceutical companies, biotechnology firms, and research institutions to jointly explore cutting-edge breakthroughs in antibody engineering, AI pharmaceuticals, and next-generation biotherapies.
We sincerely invite you to visit the GentleGen booth. Whether you are a head of R&D at a biopharmaceutical company, an algorithm expert in an AI pharmaceutical team, or a CRO/CDMO partner, GentleGen looks forward to meeting you face-to-face in Lisbon to discuss bridging the gap between AI design and wet experiments.
Conference Name:P EGS 2026 Europe
Conference Dates: November 17-19, 2026
Venue: Lisbon Congress Center | Lisbon, Portugal
GentleGen Booth: Booth 130

AIDD integrated screening and validation platform
Relying on its independently developed GentSyn-Exp3.0-G-Lab fully automated production line, GentleGen has built an integrated AIDD screening and validation platform, using a truly automated wet experiment closed loop to turn virtual sequences into real candidate molecules:
Disruptive capacity and delivery: G-Lab has achieved 8,000+ daily antibody production throughput, cumulatively delivering 1,000,000+ antibodies, and compressing the delivery cycle limit to 4 days.
End-to-end fully automated production line ensures data consistency: from AI sequence design and gene synthesis to antibody expression purification and analysis and characterization, the entire process achieves 7×24 hours of continuous high-throughput testing. The fully automated production line processes samples in parallel, greatly reducing manual intervention and ensuring experimental repeatability and stable comparability of data from the same batch.
Fully automated multi-dimensional druggability characterization: The platform not only provides affinity data but also outputs standardized multi-dimensional druggability characterization data. These high-quality, standardized wet experiment data can directly feed back into AI models, accelerate algorithm iteration, and truly open the AIDD wet-dry closed loop.
Information Security and Intellectual Property Protection: Full-link data protection supports API system integration, ensuring efficient data flow while strictly safeguarding customers' AI sequence experiment data and core intellectual property.
At the booth, our team will be there to answer your technical challenges in antibody engineering, high-throughput screening, and automated validation. At the same time, we have prepared detailed technical materials and interactive gifts, looking forward to your visit.
If you wish to make an appointment for discussions before the exhibition or learn more about related services, please send an email to: marketing@gentlegen.com.
In November, let's gather in Lisbon at booth 130 to explore the limitless possibilities of biopharmaceutical research together!